Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

CardioDx unveils positive study results of Corus CAD gene expression test

CardioDx has unveiled the study results of a clinical utility study of the Corus CAD gene expression test in the real-world primary care setting for evaluating patients with signs and symptoms suggestive of obstructive coronary artery disease (CAD).

The multicenter, prospective study showed that clinicians’ diagnostic decision making was significantly influenced by integrating Corus CAD early to assess patients for obstructive CAD.

The clinician’s diagnostic strategy was assessed before and after the Corus CAD results were revealed.

Following Corus CAD testing, clinicians modified their diagnostic strategy in 58% of patients (p<0.001). Among the 127 patients with low Corus CAD scores (less than or equal to 15), 60% (76/127) saw a reduction in testing and only 2% (3/127) had increased testing, according to the company.

CardioDx chief medical officer Mark Monane said that the new advances in understanding human genomics combined with evolving research on atherosclerosis have given the company a deeper understanding of how a person’s sex and biology influence their CAD evaluation.

"The result of this study, combined with the IMPACT-Cardiology study, demonstrate that Corus CAD use enables customized care for each individual patient, potentially leading to improved patient outcomes, a reduction in unnecessary imaging and invasive procedures, and lower overall healthcare expenditures," Monane added.